Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

B1160000

Bupivacain -hydrochlorid

European Pharmacopoeia (EP) Reference Standard

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C18H28N2O · HCl
CAS-Nummer:
18010-40-7
Molekulargewicht:
324.89
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

bupivacaine

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

InChI

1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H

InChIKey

SIEYLFHKZGLBNX-UHFFFAOYSA-N

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Bupivacaine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1078507

Bupivacainhydrochlorid, United States Pharmacopeia (USP) Reference Standard

Y0000088

Bupivacain Unreinheit B, European Pharmacopoeia (EP) Reference Standard

Y0000089

Bupivacain Unreinheit E, European Pharmacopoeia (EP) Reference Standard

Y0001575

Bupivacain Unreinheit F, European Pharmacopoeia (EP) Reference Standard

1078529

Bupivacain-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1078518

Bupivacain-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

PHR1738

Bupivacaine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1756

Bupivacain-verwandte Verbindung B, Pharmaceutical Secondary Standard; Certified Reference Material

BP479

Bupivacain -hydrochlorid, British Pharmacopoeia (BP) Reference Standard

PHR9084

(S)-Bupivacain, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR9147

N-(2,6-Dimethylphenyl)-pyridin-2-carboxamid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Piktogramme

Skull and crossbones
GHS06

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 1 Inhalation - Acute Tox. 2 Dermal - Acute Tox. 2 Oral

Lagerklassenschlüssel

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

≥98% (HPLC)

Sigma-Aldrich

SML1444

(±)-Mepivacaine hydrochloride

Bupivacain Unreinheit F European Pharmacopoeia (EP) Reference Standard

Y0001575

Bupivacain Unreinheit F

Lidocain powder

Sigma-Aldrich

L7757

Lidocain

Lidocain -hydrochlorid British Pharmacopoeia (BP) Reference Standard

BP214

Lidocain -hydrochlorid

Lidocainhydrochlorid European Pharmacopoeia (EP) Reference Standard

L0600000

Lidocainhydrochlorid

Lidocainhydrochlorid Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1257

Lidocainhydrochlorid

David R Walega et al.
Journal of oral & facial pain and headache, 28(2), 171-175 (2014-05-14)
Burning Mouth Syndrome (BMS) is a chronic painful disorder characterized by unremitting bilateral burning oral pain often associated with taste abnormalities and complaints of dry mouth. The diagnosis is made by history and symptom presentation in the absence of an
David Buck et al.
Anesthesia and analgesia, 119(1), 137-140 (2014-06-20)
An otherwise healthy 11-month-old, 8-kg infant presented for an elective circumcision. After a penile block with an excessive dose of 0.5% bupivacaine, the patient progressed to ventricular tachycardia. He was resuscitated with intralipid and had an uneventful recovery. The case
Michael J Beebe et al.
Clinical orthopaedics and related research, 472(5), 1394-1399 (2013-07-17)
Continuous femoral nerve block has been shown to decrease opioid use, improve postoperative pain scores, and decrease length of stay. However, several studies have raised the concern that continuous femoral nerve block may delay patient ambulation and increase the risk
Mingquan Chen et al.
Anesthesia and analgesia, 118(4), 863-868 (2014-03-22)
In this study, we sought to determine the median effective dose (ED50) for motor block of intrathecally administered plain bupivacaine in adults (20-80 years) and to assess the effect of age on ED50 required for motor block. This study was
Michael R Fettiplace et al.
Anesthesiology, 120(4), 915-925 (2014-02-06)
Recent publications have questioned the validity of the "lipid sink" theory of lipid resuscitation while others have identified sink-independent effects and posed alternative mechanisms such as hemodilution. To address these issues, the authors tested the dose-dependent response to intravenous lipid
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.